戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              RTFs reconstituted with the mutant R37C TnI exhibited re
2                       The study included 103 RTF letters containing a total of 644 identified FDA ref
3 ublicly disclosed the existence of 16 of 103 RTF letters (15.5%); however, only 5.4% of applicant-dis
4 tion and the signal-to-noise ratio, to assay RTF and individually pooled CTF and OTF samples for 80 c
5 xclusively: 1) 12 mg Fe/L processed in cans (RTF-12), 2) formula in glass bottles with 12 mg Fe/L and
6 fferent from, that of two well characterized RTF IEGs (c-fos and zif268) after learning.
7        In sub-maximal activation conditions, RTFs are not fully active, enabling direct observation o
8 ament (seven actins), whereas with E59D/D75Y RTFs, the number of binding sites was reduced by approxi
9 asses: (1) regulatory transcription factors (RTFs), which can broadly influence cell function dependi
10 aluate the effects of feeding ready-to-feed (RTF) formulas exposed to different heat treatments to in
11 ition from a room temperature ferromagnetic (RTF) to a superparamagnetic material.
12  troponin complex, regulated thin filaments (RTF), and the Ca(2+) sensitivity of contraction and ATPa
13                    Regulated thin filaments (RTFs) tightly control striated muscle contraction throug
14 ation in human reconstituted thin filaments (RTFs) using fluorometry.
15  parameters of reconstituted thin filaments (RTFs).
16 e incomplete, the FDA issues refuse-to-file (RTF) letters identifying deficiencies.
17 the FDA comments that, while not a basis for RTF letters, conveyed important information to applicant
18 tase activity in infants fed canned formula (RTF-12).
19 an unprecedented reverse transcription-free (RTF) approach for converting genomic RNA into DNA.
20 nformation were extracted and cataloged from RTF letters: (1) the reasons why the FDA refused to file
21  plants (restricted taxonomic functionality, RTF).
22                           Why the FDA issues RTF letters and how often the letters and their contents
23 osin-S1 (S1-GFP) to follow the activation of RTF tightropes.
24 significantly enhanced Ca(2+) sensitivity of RTF activation relative to control.
25 ing the study time frame, 98 (4.0%) received RTF letters.
26 regulatory decision-making processes and the RTF reasons that could delay availability of therapies t
27 e-separated domains were responsible for the RTF properties of the nanostructured BCP materials.
28 sal reasons that the FDA had provided in the RTF letters.
29 lobin values were significantly lower in the RTF-12 group than in all other groups at ages 4 and 5 mo
30 and 5 mo and serum ferritin was lower in the RTF-12 group than in the STP-12 group at age 5 mo.
31                      A total of 26.2% of the RTF letters (27 of 103) identified presubmission advice
32 A conversion and amplification stages of the RTF-EXPAR assay in a single step results in the detectio
33 iometry of myosin subfragment-1 (S-1) to the RTF.
34                  The FDA does not make these RTF letters public at the time of issuance.
35                              Using wild type RTFs, 4.8 mol S-1 was bound per mol filament (seven acti